After a failed listing on the Beijing Stock Exchange and a delisting from the New Third Board, Puqi Pharma refiled for an IPO on the Hong Kong Stock Exchange on July 24, aiming to seize a critical window as its core product nears commercialization in a last-ditch effort.
This biotech company, focused on topical targeted therapies for immune-inflammatory diseases, saw its New Drug Application (NDA) for Pumicitinib (PG-011) gel accepted by the National Medical Products Administration in February 2026, placing it just one step away from commercialization. However, financial data reveals that from 2024 through the first four months of 2026, the company's R&D spending totaled 1.46 billion yuan, 1.28 billion yuan, and 54.492 million yuan, respectively, accumulating nearly 400 million yuan in losses over the period. By the end of April 2026, its net assets had turned negative, standing at minus 7.191 million yuan, leaving it insolvent.
Facing increasingly fierce competition in the atopic dermatitis space—with three oral JAK1 inhibitors already approved in China and 22 drug candidates in development—Puqi Pharma is differentiating itself with topical gel and nasal spray formulations. It has secured commercialization partnerships with Jumpcan Pharmaceutical and Simcere Pharmaceutical to pave the way for its product launch. This shift to Hong Kong listing represents both another crucial adjustment in its capital market strategy and a financial "defensive battle" for survival, ensuring cash flow and continued R&D.
Capitalizing on the JAK Inhibitor Billion-Dollar Market via 'Local Delivery'
Amid safety concerns surrounding systemic JAK inhibitor treatments and the increasingly apparent efficacy limitations of traditional topical drugs, Puqi Pharma has chosen a differentiated path: "avoiding the mainstream and forging a new route." By confining potent JAK1/2 inhibition to local lesions, it targets two major immune-inflammatory disease markets—atopic dermatitis and allergic rhinitis—using gel and nasal spray formulations. This strategic choice essentially rebalances the "efficacy-safety-compliance" triangle—enhancing safety enough to support long-term chronic disease management without excessively sacrificing efficacy, thereby attracting a large segment of mild-to-moderate patients who are wary of oral systemic drugs.
From a market size perspective, this path has clear commercial logic. According to Frost & Sullivan, China's atopic dermatitis drug market is projected to grow from 13.2 billion yuan in 2025 to 48.4 billion yuan in 2033, a compound annual growth rate of 17.6%. Meanwhile, the allergic rhinitis drug market is expected to rise from 5.3 billion yuan to 23.6 billion yuan, with a CAGR exceeding 20%. The combined long-term potential of over 70 billion yuan for these two markets is sufficient to accommodate a niche leader with a differentiated advantage.
Puqi Pharma's key asset is its "time window." As the first topical JAK inhibitor gel to submit an NDA in China, Pumicitinib gel is expected to be approved between 2026 and 2027, giving it at least a 12 to 18-month lead over subsequent competitors.
However, formulation innovation is not risk-free arbitrage. While topical gels avoid the systemic exposure risks of oral JAK inhibitors, their efficacy heavily depends on drug permeability through the skin, patient compliance, and individual variations in lesion sites. Clinical data shows promising results for Pumicitinib gel on key efficacy endpoints, but whether it can replicate these results in real-world settings remains to be seen post-launch. Additionally, three other JAK inhibitor topical formulations in China are in Phase III trials or NDA stages, directly determining the length of Puqi Pharma's window as competitors advance.
From a financial perspective, the success of this strategy hinges not only on product approval but also on the company's ability to leverage established channel partnerships with Jumpcan Pharmaceutical and Simcere Pharmaceutical within 12 months of approval to achieve rapid distribution, converting first-mover advantage into tangible prescription volumes and market share. If the commercialization ramp-up falls short, the first-mover advantage could be quickly diluted by incoming competitors, and the valuation logic could shift from a "unique product premium" to a "homogeneous competition discount."
How Will the Commercialization Path Intersect with the Capital Chain Dilemma?
For a biotech company founded nearly a decade ago, with cumulative losses of approximately 400 million yuan and already insolvent, the act of filing for a Hong Kong IPO itself reflects the urgency of its current financial situation and the countdown pressure for commercialization. As of April 30, 2026, Puqi Pharma's net assets had turned negative at minus 7.191 million yuan, meaning that without a new round of financing in the near term, the company faces a real risk of a working capital chain rupture. From this perspective, the Hong Kong 18A listing is not a strategic option but a survival necessity—the "final push" as the core product nears approval is precisely when the company's cash flow is most strained, as R&D expenses, commercialization preparation costs, and production facility investments continue before approval, with no revenue yet generated.
But risk also presents opportunity. The NDA for Pumicitinib gel was accepted by the National Medical Products Administration in February 2026, and under standard review timelines, it could be approved in the first half of 2027. This means the company is in the "darkest period before dawn," but once approved, cash flow will hit a turning point from zero to one.
In its commercialization strategy, Puqi Pharma has adopted a pragmatic "asset-light" approach—partnering with established firms like Jumpcan Pharmaceutical and Simcere Pharmaceutical rather than building a large in-house sales team. From a financial standpoint, this decision has dual significance: it greatly reduces sales expenses' drain on cash flow, concentrating limited funds on subsequent indication expansion (pediatric atopic dermatitis, prurigo nodularis, vitiligo, etc.) and advancing the nasal spray's Phase III trial. On the other hand, by leveraging partners' dermatology and respiratory channel resources, it aims for rapid volume growth after approval, shortening the time to break-even from the approval date.
Nevertheless, the certainty of commercial monetization still requires careful assessment. The topical treatment field for atopic dermatitis already includes multiple competitors like corticosteroids, calcineurin inhibitors, and PDE-4 inhibitors, some of which have entered volume-based procurement or medical insurance catalogs with mature pricing systems. As a new drug with a novel mechanism, Pumicitinib gel faces the dilemma of "high price makes insurance entry difficult, while low price cannot cover R&D costs." The allergic rhinitis nasal spray faces even steeper market education challenges—treating allergic rhinitis with JAK inhibitors is a completely new mechanism, requiring time to cultivate physician prescription habits, while nasal steroids and antihistamines already dominate most of the market at low prices.
Thus, the critical milestone for Puqi Pharma's transition from Biotech to Biopharma is not the NDA approval date, but whether within 12 months of approval it can achieve prescription volumes that reach the break-even point. If the IPO financing is completed smoothly, the product is approved as expected, and commercialization partnerships are effectively implemented, the company could achieve revenue breakthroughs and narrow losses around 2028. However, if any step faces delays or underperformance, pressure on the capital chain will intensify again, potentially triggering valuation adjustment clauses or revaluation risks. The final outcome of this "race between the capital chain and commercialization" will determine whether Puqi Pharma becomes a niche leader in local immune-inflammatory treatment or another regrettable Biotech case that stalls after product approval.
Comments